Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $220.00 Price Target at Wells Fargo & Company

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price lowered by Wells Fargo & Company from $253.00 to $220.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock.

ALNY has been the subject of several other reports. HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday. Barclays dropped their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Zacks Research downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Jefferies Financial Group lifted their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a research note on Tuesday, September 8th. Finally, Bank of America restated a “buy” rating and set a $287.00 price target (down from $460.00) on shares of Alnylam Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $317.95.

Alnylam Pharmaceuticals Trading Down 5.2%

Shares of NASDAQ ALNY opened at $165.00 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a one year low of $163.30 and a one year high of $479.79. The business has a 50-day moving average price of $236.49 and a two-hundred day moving average price of $286.19. The firm has a market capitalization of $22.08 billion, a PE ratio of 8.57 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 246.94% and a net margin of 52.85%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.90 EPS. As a group, analysts predict that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rakuten Investment Management Inc. grew its position in Alnylam Pharmaceuticals by 13.0% in the third quarter. Rakuten Investment Management Inc. now owns 20,289 shares of the biopharmaceutical company’s stock worth $5,155,000 after acquiring an additional 2,328 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $527,000. GraniteShares Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 12.7% during the 3rd quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 205 shares in the last quarter. Traynor Capital Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 22.6% during the 3rd quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock valued at $3,163,000 after purchasing an additional 2,360 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $18,226,000. Institutional investors own 92.97% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.